Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection

American Journal of Gastroenterology

Volumn 104, Issue 3, 2009, Pages 598-604

  Hsu, Ching Sheng ^a,b   Liu, Chen Hua ^b   Liu, Chun Jen ^b   Wang, Chia Chi ^a   Chen, Chi Ling ^b   Lai, Ming Yang ^b   Chen, Pei Jer ^b   Chen, Ding Shinn ^b   Kao, Jia Horng ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; RNA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STRATIFICATION; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 84983722768     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.125     Document Type: Article

References (41)

1. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000;15 Suppl:E91-6.
2. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 1995;25:27-32.
3. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
5. Akuta N, Suzuki F, Kawamura Y et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007;79:1686-95.
6. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42.
7. Lonardo A, Adinolfi LE, Loria P et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
8. Dharancy S, Malapel M, Perlemuter G et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005;128:334-42.
9. O ' Leary JG, Chan JL, McMahon CM et al. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007;45:895-8.
10. Mehta SH, Brancati FL, Strathdee SA et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38:50-6.
11. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089-97.
12. Aizaki H, Lee KJ, Sung VM et al. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004;324:450-61.
13. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
14. Petit JM, Benichou M, Duvillard L et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003;98:1150-4.
15. Barba G, Harper F, Harada T et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997;94:1200-5.
16. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
17. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-9.
18. Gopal K, Johnson TC, Gopal S et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006;44:335-40.
19. Fernandez-Rodriguez CM, Lopez-Serrano P, Alonso S et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006;24:507-12.
20. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005;102:2561-6.
21. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007;105:145-50.
22. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
23. Fartoux L, Poujol-Robert A, Guechot J et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
24. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
25. Reddy KR, Govindarajan S, Marcellin P et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008;15:129-36.
26. Asselah T, Rubbia-Brandt L, Marcellin P et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:123-30.
27. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
28. Hsu CS, Liu CJ, Liu CH et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008;28:271-7.
29. Hsu CS, Liu CJ, Lai MY et al. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007;50:310-5.
30. Kao JH, Lin HH, Chen PJ et al. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 1996;31:224-7.
31. Ohno O, Mizokami M, Wu RR et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201-7.
32. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
33. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
34. Huang KC. Obesity and its related diseases in Taiwan. Obes Rev 2008;9 (Suppl 1):32-4.
35. Amemiya F, Maekawa S, Itakura Y et al. Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis 2008;197:361-70.
36. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 2007;3:e108.
37. von Hahn T, Rice CM. Hepatitis C virus entry. J Biol Chem 2008;283:3689-93.
38. Fanning L, Kenny E, Sheehan M et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999;29:904-7.
39. Bugianesi E, Marchesini G, Gentilcore E et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology 2006;44:1648-55.
40. Rodriguez-Torres M, Govindarajan S, Sola R et al. Hepatic steatosis in HCV/HIV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008;48:756-64.
41. Liu CJ, Jeng YM, Chen PJ et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther 2005;10:405-15.